Maitland K
Sainna H
Connon R
Ouattara SM
Sunyoto T
Chara A
Ogundipe OF
Maguina AS
Hamaluba M
Olupot-Olupot P
Alaroker F
Okiror W
Aromut D
Mwajombo E
Oguda E
Mogaka C
Langendorf C
Dewez JE
Ciglenecki I
Gibb DM
Petrucci R
Coldiron ME
George EC
Gastrosam trial group
Lancet Child Adolesc Health. 2026;10319-329
BACKGROUND: International guidelines for treatment of children with severe acute malnutrition advise against giving standard oral rehydration solutions (ORS) for dehydration secondary to diarrhoea. Instead, they recommend exclusive use of low-sodium rehydration solution for malnutrition (ReSoMal), due to concerns about both sodium and fluid overload. Supportive evidence is lacking, warranting reappraisal of this guidance. We aimed to assess the safety and superiority of standard WHO-ORS versus ReSoMal. METHODS: GASTROSAM was a phase 2, factorial, open-label, superiority randomised controlled trial conducted at six hospitals in four African countries (Kenya, Niger, Nigeria, and Uganda). Children aged 6 months to 12 years with severe acute malnutrition who were admitted to hospital with severe (stratum A) or moderate (stratum B) dehydration and diarrhoea were randomly assigned in a 1:1 ratio to receive ReSoMal or low-osmolarity WHO-ORS. A simultaneous randomisation in stratum A compared two intravenous strategies versus an oral control rehydration strategy (results reported elsewhere). Children with severe dehydration (stratum A) received their allocated ORS as soon as possible. The primary endpoint was change in sodium concentration at 24 h from baseline in all randomised participants and analysed on an intention-to-treat basis. Children with lived experience were not involved in the study design. The trial is registered on the ISRCTN registry (ISRCTN76149273) and the Pan-African Clinical Trials Registry (PACTR202103852542919). FINDINGS: Between Sept 2, 2019, and Oct 27, 2024, 415 eligible children were enrolled (218 [53%] male; 197 [47%] female); 272 were enrolled into stratum A (137 to ReSoMal and 135 to WHO-ORS) and 143 were enrolled into stratum B (69 to ReSoMal and 74 to WHO-ORS). Children were followed up for 28 days; 11 (3%) were lost to follow-up or withdrew. The primary endpoint was assessed in 387 (93%) of 415 participants. The increase in sodium concentration was similar in both groups (5.3 mmol/L [SD 8.1] with ReSoMal vs 5.0 mmol/L [7.6] with WHO-ORS; mean difference for WHO-ORS vs ReSoMal -0.6 [95% CI -1.9 to 0.7], p=0.37). There was no difference in day 28 mortality between the WHO-ORS and ReSoMal groups (19 [9%] vs 24 [12%]; adjusted hazard ratio 0.76 [95% CI 0.41 to 1.41], p=0.39). Fluid overload events (pulmonary oedema and cardiac overload) were actively monitored: none was observed. INTERPRETATION: WHO-ORS resulted in similar outcomes to ReSoMal, and neither strategy led to fluid overload. This finding informs the simplification of guidelines supporting the use of WHO-ORS for the management of dehydration in children regardless of nutritional status. FUNDING: Joint Global Health Trials Scheme of the UK Medical Research Council, UK Department for International Development, Wellcome, and Medecins Sans Frontieres.
